Early detection of ulcerative colitis-associated colorectal cancer

Yu, Zhen; Luo, Can; Hu, Zhang

doi:10.1093/gastro/goy010

Cited by 39 publications

(31 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is widely known that patients diagnosed with UC present a higher risk of developing CRC, with statistics showing that the risk may be 2–3 times higher compared to the general population [76,77,78]. Tumour initiation and progression processes are dependent of multiple factors, especially regarding the influence of the environment and diet, with the latter being able to either ameliorate or even increase CRC risk [79].…”

Section: Discussionmentioning

confidence: 99%

Reduction of Inflammation and Colon Injury by a Spearmint Phenolic Extract in Experimental Bowel Disease in Mice

et al. 2019

View full text Add to dashboard Cite

Background: Inflammatory Bowel Diseases (IBD) encompasses both Crohn’s Disease and Ulcerative Colitis, known to be connected to an enlarged risk for developing colorectal cancer (CRC). Spearmint (Mentha spicata L.) is a Mediterranean plant used as an aromatic agent, and studies have mainly focused on the essential oil suggesting an anti-inflammatory activity. This work aimed to perform a preliminary screening of the in vivo anti-inflammatory effects of a spearmint phenolic extract in an acute inflammation model, in a chronic inflammation model of colitis, and also study the effects in vitro on a colon cancer model. Methods: Spearmint extract was administered to rats of a paw oedema model (induced by carrageenan) and to mice from a TNBS-induced colitis model in parallel with studies using HT-29 CRC cells. Results: Administration of the extract led to reduced paw inflammation, reduction of colon injury and inflammation, with attenuation of histological markers, and reduction of iNOS expression. It repressed the in vitro movement of HT-29 cells in a wound healing assay. Conclusions: These findings suggest that spearmint extract exhibits acute and chronic anti-inflammatory activity and is able to inhibit migration of cancer cells, suggesting a potential role in the supplementary therapy of IBD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Reduction of Inflammation and Colon Injury by a Spearmint Phenolic Extract in Experimental Bowel Disease in Mice

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Although 96% of all CRCs do not develop in the context of pre-existing inflammation, the roles of chronic inflammation, tumor-elicited inflammation, the tumor microenvironment (TME), and partially adaptive immune cells in CRC development, have been established, particularly in the context of their interaction with gut dysbiosis [18][19][20][21][22][23]. Colitis-associated cancer (CAC) is a specific subset of CRC characterized by its implication with inflammation that accounts for 1%-2% of all CRCs [24]. CAC, originating from either the chronic inflammation in both the colon and the small intestine, or solely the colon, as is the case of Crohn's disease (CD) or ulcerative colitis (UC), respectively, is classified by the excessive activation and recruitment of immune cells that produce inflammatory cytokines, such as TNF, IL-17, IL-23 and IL-6, that lead to the propagation of an inflammatory and possibly premalignant environment [25].…”

Section: Origins Of Crcmentioning

confidence: 99%

Immunotherapy, Inflammation and Colorectal Cancer

Lichtenstern

Ngu

Shalapour

et al. 2020

Cells

215

154

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer type, and third highest in mortality rates among cancer-related deaths in the United States. Originating from intestinal epithelial cells in the colon and rectum, that are impacted by numerous factors including genetics, environment and chronic, lingering inflammation, CRC can be a problematic malignancy to treat when detected at advanced stages. Chemotherapeutic agents serve as the historical first line of defense in the treatment of metastatic CRC. In recent years, however, combinational treatment with targeted therapies, such as vascular endothelial growth factor, or epidermal growth factor receptor inhibitors, has proven to be quite effective in patients with specific CRC subtypes. While scientific and clinical advances have uncovered promising new treatment options, the five-year survival rate for metastatic CRC is still low at about 14%. Current research into the efficacy of immunotherapy, particularly immune checkpoint inhibitor therapy (ICI) in mismatch repair deficient and microsatellite instability high (dMMR–MSI-H) CRC tumors have shown promising results, but its use in other CRC subtypes has been either unsuccessful, or not extensively explored. This Review will focus on the current status of immunotherapies, including ICI, vaccination and adoptive T cell therapy (ATC) in the treatment of CRC and its potential use, not only in dMMR–MSI-H CRC, but also in mismatch repair proficient and microsatellite instability low (pMMR-MSI-L).

show abstract

“…Moreover, there are overall poorer long-term prognoses for patients diagnosed with IBD-associated CRC [7–9]. Colonoscopy surveillance has been widely accepted as an effective method in reducing the risk of IBD-associated CRC [5, 10, 11]. However, it is crucial to identify risk factors related to the development of colorectal neoplasia in patients with underlying IBD.…”

Section: Introductionmentioning

confidence: 99%

Risk factors for colorectal neoplasia in patients with underlying inflammatory bowel disease: a multicenter study

Zheng

Huang

et al. 2018

Gastroenterology Report

View full text Add to dashboard Cite

BackgroundThis study sought to evaluate the risk factors for the development of colitis-associated neoplasia (CAN) in Chinese patients with inflammatory bowel disease (IBD).MethodsIBD patients who developed CAN between 1999 and 2016 were identified from eight medical centers. In addition to initial pathology evaluation, a CAN diagnosis was confirmed by two expert pathologists. Patients with CAN (n = 29) were compared with non-CAN controls (n = 87). Matching was performed for gender and IBD type with a ratio of three controls to one subject.ResultsOf the 29 patients with CAN, 8 (27.6%) had colorectal cancer (CRC), 20 (69.0%) had a final diagnosis of low-grade dysplasia and 1 (3.4%) had high-grade dysplasia. Multivariate analysis revealed that an older age at the time of IBD diagnosis and a longer IBD duration were independent risk factors for the development of CAN, with odds ratios of 1.09 [95% confidence interval (CI): 1.04–1.14, P < 0.001] and 1.14 (95% CI: 1.03–1.27, P = 0.013), respectively. Comparison between IBD patients with CRC and those with dysplasia indicated that the former were older at the time of IBD diagnosis (P = 0.012) and had longer IBD durations (P = 0.019).ConclusionsOlder age at the time of IBD diagnosis and longer IBD duration were found to be associated with the development of CAN in IBD patients.

show abstract

Early detection of ulcerative colitis-associated colorectal cancer

Cited by 39 publications

References 92 publications

Reduction of Inflammation and Colon Injury by a Spearmint Phenolic Extract in Experimental Bowel Disease in Mice

Reduction of Inflammation and Colon Injury by a Spearmint Phenolic Extract in Experimental Bowel Disease in Mice

Immunotherapy, Inflammation and Colorectal Cancer

Risk factors for colorectal neoplasia in patients with underlying inflammatory bowel disease: a multicenter study

Contact Info

Product

Resources

About